TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from HUTCHMED (China) ( (HK:0013) ) is now available.
HUTCHMED (China) Limited announced significant advancements in its research and development efforts, particularly highlighting its new Antibody-Targeted Therapy Conjugate (ATTC) platform, which integrates monoclonal antibodies with small-molecule inhibitors to enhance precision oncology. The lead candidate, HMPL-A251, shows promising preclinical results in targeting the PAM pathway, with plans to enter clinical development by late 2025. Additionally, HUTCHMED reported progress in several late-stage clinical trials, including studies on fruquintinib, savolitinib, surufatinib, sovleplenib, and fanregratinib, indicating potential advancements in treatment options for various cancers and immunological conditions.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates primarily in the oncology and immunology sectors, aiming to address critical unmet medical needs through innovative treatment solutions.
YTD Price Performance: 3.15%
Average Trading Volume: 9,843,379
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$20.29B
Learn more about 0013 stock on TipRanks’ Stock Analysis page.